17.81
-0.18(-1.00%)
Currency In USD
| Previous Close | 17.99 |
| Open | 17.81 |
| Day High | 18.32 |
| Day Low | 17.35 |
| 52-Week High | 43.99 |
| 52-Week Low | 16.65 |
| Volume | 2.98M |
| Average Volume | 2.29M |
| Market Cap | 2.24B |
| PE | -11.13 |
| EPS | -1.6 |
| Moving Average 50 Days | 21.85 |
| Moving Average 200 Days | 29.61 |
| Change | -0.18 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $1,269.42 as of May 09, 2025 at a share price of $17.81. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $541.34 as of May 09, 2025 at a share price of $17.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire Inc.
Apr 30, 2025 11:00 AM GMT
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025,
Apellis Announces Craig Wheeler to Join the Board of Directors
GlobeNewswire Inc.
Apr 21, 2025 11:00 AM GMT
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effect
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire Inc.
Apr 01, 2025 11:00 AM GMT
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review desi